^
    5d
    Real-world study of SHR-1210 plus apatinib in the treatment of BRAF-negative mucosal melanoma: efficacy, safety and implications of precision medicine. (PubMed, Front Immunol)
    However, the sample size is relatively small and needs to be increased for further research. https://clinicaltrials.gov/study/NCT03986515, identifier NCT03986515.
    Clinical • Journal • Real-world evidence
    |
    BRAF (B-raf proto-oncogene)
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    5d
    Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer (clinicaltrials.gov)
    P2, N=124, Recruiting, Air Force Military Medical University, China
    New P2 trial • Real-world evidence
    |
    cisplatin • gemcitabine • AiTan (rivoceranib) • AiRuiLi (adebrelimab)
    6d
    Apatinib and Adebrelimab Exhibit Synergistic Antitumor effects in Small Cell Lung Cancer: An In Vitro Study. (PubMed, Curr Med Chem)
    In summary, the combination of Apa and Ade represented a promising innovative therapeutic strategy for SCLC.
    Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • KDR (Kinase insert domain receptor) • IFNG (Interferon, gamma) • STAT3 (Signal Transducer And Activator Of Transcription 3) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    PD-L1 expression
    |
    AiTan (rivoceranib) • AiRuiLi (adebrelimab)
    11d
    CLARITY-Gastric 01: AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 (clinicaltrials.gov)
    P3, N=572, Recruiting, AstraZeneca | Active, not recruiting --> Recruiting
    Enrollment open
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 expression • CLDN18.2 positive • CLDN1 positive
    |
    paclitaxel • docetaxel • AiTan (rivoceranib) • Cyramza (ramucirumab) • irinotecan • Lonsurf (trifluridine/tipiracil) • sonesitatug vedotin (AZD0901)
    15d
    Perioperative immunotherapy for hepatocellular carcinoma: adjuvant, neoadjuvant, and biomarker-guided strategies. (PubMed, Front Med (Lausanne))
    In IMbrave050, adjuvant atezolizumab plus bevacizumab initially improved recurrence-free survival (RFS), yet longer follow-up suggests attenuation of effect, influencing guideline recommendations. Perioperative combinations are emerging, including camrelizumab plus rivoceranib with improved event-free survival, and locoregional-immunotherapy strategies such as transarterial chemoembolization combined with immunotherapy-antiangiogenic regimens. Biomarker-driven selection, circulating tumor DNA for minimal residual disease, resistance-associated alterations (e.g., CTNNB1), and etiology-linked immune phenotypes, will be central to optimizing patient selection and treatment sequencing.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CTNNB1 (Catenin (cadherin-associated protein), beta 1)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    18d
    Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer (clinicaltrials.gov)
    P3, N=246, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Active, not recruiting --> Recruiting | Trial completion date: Mar 2031 --> Jun 2029 | Trial primary completion date: Sep 2030 --> Dec 2028
    Enrollment open • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • ER negative • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Halaven (eribulin mesylate)
    19d
    A clinical study of retlirafusp alfa combined with platinum-based chemotherapy and apatinib as first-line treatment for advanced NSCLC (ChiCTR2600121692)
    P4, N=35, The first affiliated hospital of anhui medical university; The first affiliated hospital of anhui medical university
    New P4 trial
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • EGFR mutation • ALK fusion • ROS1 fusion
    |
    AiTan (rivoceranib) • retlirafusp alfa (SHR-1701)
    19d
    Adebrelimab combined with apatinib and platinum-based chemotherapy for neoadjuvant treatment of potentially resectable thymic carcinoma: A single-center, single-arm, phase II clinical study (ChiCTR2600121533)
    P2, N=20, Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University); Jiangsu Province Hospital (The First Affiliated Hospital wi
    New P2 trial
    |
    AiTan (rivoceranib) • AiRuiLi (adebrelimab)
    19d
    Clinical study on maintenance therapy of olaparib combined with apatinib in patients with platinum-sensitive recurrent ovarian cancer (ChiCTR2600121505)
    P2, N=34, Anqing Municipal Hospital; Anqing Municipal Hospital
    New P2 trial • Platinum sensitive
    |
    Lynparza (olaparib) • AiTan (rivoceranib)
    19d
    A Single-Arm, Single-Center, Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination with Gemcitabine for Advanced Driver Gene-Negative Squamous Non-Small Cell Lung Cancer with Disease Progression Following PD-(L)1 Inhibitor Therapy (ChiCTR2600120009)
    P=N/A, N=33, Qingdao Central Hospital, University of Health and Rehabilitation Sciences (Qingdao Central Hospital); Qingdao Central Hospital, University of Health
    New trial
    |
    gemcitabine • AiTan (rivoceranib) • Qibeian (iparomlimab/tuvonralimab)
    19d
    Efficacy and Safety of Camrelizumab plus Rivoceranib and Local Therapy for Hepatocellular Carcinoma with Lung Metastases (CAPLocal) : A Multicentre, Single-Arm,Prospective Cohort Study (ChiCTR2600119671)
    P=N/A, N=32, Xiangya Hospital Central South University; Xiangya Hospital Central South University
    New trial
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    19d
    Multicenter, Exploratory Study of Adebrelimab Combined with Apatinib in the Treatment of PD-1 Inhibitor-Pretreated (Progressive Unresectable) Hepatocellular Carcinoma (ChiCTR2600119061)
    P4, N=30, Yantai Yuhuangding Hospital; Yantai Yuhuangding Hospital
    New P4 trial
    |
    AiTan (rivoceranib) • AiRuiLi (adebrelimab)